Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Tumour Site

Breast Cancer

Presenters

Krithikaa Sekar

Citation

Annals of Oncology (2020) 31 (suppl_6): S1241-S1254. 10.1016/annonc/annonc351

Authors

K. Sekar1, R. Lohith2, N. Radheshyam3, K. Kallur1, K. Varun2, S. Priya2, S. Siyus2

Author affiliations

  • 1 Radiation Oncology, HCG Bangalore Institute of Oncology Speciality Centre, 560027 - Bangalore/IN
  • 2 Radiation Oncology, HCG HealthCare Global Enterprises Ltd, 560037 - Bengaluru/IN
  • 3 Medical Oncology, HCG HealthCare Global Enterprises Ltd, 560037 - Bengaluru/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 33P

Background

FDG PET is used in staging, early prediction of treatment response, monitoring metastatic tumours and in disease status assessment post completion of treatment. In patients undergoing upfront surgery, a significant standardized uptake value (SUV) is associated with pathological node positivity. In patients receiving anterior chemotherapy, studies have shown that a reduction in size and SUV of primary tumour or involved node predicts response to therapy. However based on our observation, the predictive value of PETCT appeared to differ between the upfront setting and post-neoadjuvant chemotherapy (NACT) setting. Our study compares the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of FDG-PET in predicting pathological axillary nodal involvement in 50 upfront surgery and 50 post-NACT patients.

Methods

This study was conducted between the years 2015 to 2016. Clinical, histopathological and radiological details were obtained from patient records. 50 upfront surgery and 50 post-NACT patient details were reviewed for PETCT nodal status and histopathological nodal status and the following parameters analysed. 1)Sensitivity; 2)Specificity; 3)Positive Predictive Value; 4)Negative Predictive Value

Results

In upfront surgery cases the total number of TP was 21, FP was 2, FN was 12 and TN was 15. In post NACT setting, it was 5, 1, 10 & 34 respectively. Table: 33P

Upfront PETCT Post NACT PETCT
Sensitivity 63.6% 33.3%
Specificity 88.2% 97.1%
Positive Predictive Value 91.3% 88.3%
Negative Predictive Value 55.3% 77.2%

Conclusions

Although metabolic response monitoring post chemotherapy is a useful tool,the sensitivity appears to be lower in predicting pathological node positivity. That is, the proportion of patients with positive pathological node having PET positivity appears to be lower. A practical application of the same would be, to complete all cycles of chemotherapy prior to surgery, irrespective of an interim PETCT complete nodal response, to attain maximal Pathological Complete Response rates.To conclude, the rate of PETCT predictivity of pathological axillary nodal positivity appears to differ between upfront surgery and post-NACT setting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Krithikaa Sekar.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.